NCT06466798 2026-01-08Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS MalignanciesThe University of Texas Health Science Center, HoustonPhase 1 Withdrawn